Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II

Fineline Cube Jul 22, 2026
Company Deals

TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal

Fineline Cube Jul 22, 2026
Company Deals

Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody

Fineline Cube Jul 22, 2026
Company Deals

Grand Pharma Partners with Siemens Healthineers to Commercialize AcuNav Lumos 4D ICE Catheter in China’s Structural Heart Market

Fineline Cube Jul 21, 2026
Company Deals Digital

Insilico Medicine Forms Quantum-AI Alliance with Byterna and DuneQ to Accelerate Next-Generation RNA and Peptide Therapeutics

Fineline Cube Jul 21, 2026
Policy / Regulatory

China Launches 12th Batch of National Drug Procurement with Vonoprazan and Vitamin B6 Drawing Record Competition

Fineline Cube Jul 21, 2026
Company Drug

Youcare Pharmaceutical Receives NMPA Approval for YKYY033 Clinical Trials Across Multiple Thrombotic Indications

Fineline Cube Jul 22, 2026
Company Drug

Junshi Biosciences Receives NMPA Acceptance for Toripalimab Expanded Indication in Resectable Stage II–III NSCLC

Fineline Cube Jul 22, 2026
Company Drug

BMS and 2seventy Bio’s Abecma Faces FDA Review Extension

Fineline Cube Nov 21, 2023

The US Food and Drug Administration (FDA) has postponed the target action date for Bristol...

Company Deals

Suzhou Porton Biologics Partners with Asclepius Technology for NK Cell Project

Fineline Cube Nov 21, 2023

China-based Contract Development and Manufacturing Organization (CDMO) Suzhou Porton Biologics Ltd has entered into a...

Company

Shanghai Pharmaceuticals’ Chairman Zhou Jun Resigns Amid Investigation

Fineline Cube Nov 21, 2023

Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), a leading Chinese pharmaceutical distribution company, has announced...

Company Deals

VIVA Biotech Holdings Secures Nearly USD 210 Million in Financing Round

Fineline Cube Nov 21, 2023

China-based Contract Research Organization (CRO) VIVA Biotech Holdings (HKG: 1873) has announced the completion of...

Company Drug

Jiangsu Aidea Pharmaceutical’s AINUOVIRINE Receives Priority Review Status from CDE

Fineline Cube Nov 21, 2023

Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a Chinese pharmaceutical company, has announced that its...

Company Drug

Medilink Therapeutics’ YL201 Earns Orphan Drug Designation for Esophageal Cancer

Fineline Cube Nov 21, 2023

Suzhou-based Medilink Therapeutics has announced that it has obtained orphan drug designation (ODD) from the...

Company Deals

Chiesi Farmaceutici Acquires Global Rights to Haisco Pharmaceutical’s HSK31858 for Respiratory Diseases

Fineline Cube Nov 21, 2023

Italy-based Chiesi Farmaceutici S.p.A has announced a licensing agreement with China-based Haisco Pharmaceutical Group Co.,...

Company Deals

Fosun Pharmaceutical’s US Subsidiary Partners with Treehill Partners for Clinical-Stage Investments

Fineline Cube Nov 21, 2023

Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196; SHA: 600196) through its US subsidiary, Fosun Pharma...

Company Deals

Jiangsu Aidea Pharmaceutical Partners with Fidson Healthcare for HIV/AIDS Treatments in Nigeria

Fineline Cube Nov 20, 2023

China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has reportedly entered into a strategic cooperation...

Company Deals

GE Healthcare’s Shanghai Innovation Hub Onboards Initial Start-Ups

Fineline Cube Nov 20, 2023

GE Healthcare’s (NASDAQ: GEHC) newly established Shanghai innovation center, dedicated to advancing healthcare projects, has...

Company Drug

BeiGene’s Brukinsa Secures Additional EU Approval for Follicular Lymphoma Treatment

Fineline Cube Nov 20, 2023

BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has achieved its latest global approval for...

Company Deals

WuXi Biologics’ Subsidiary WuXi XDC Lists on Hong Kong Stock Exchange

Fineline Cube Nov 20, 2023

WuXi Biologics (HKG: 2269) has successfully spun off its conjugate drug-focused subsidiary, WuXi XDC Cayman...

Company Deals

Winning Health Partners with Shanghai Seventh People’s Hospital on Medical AI Services

Fineline Cube Nov 20, 2023

Shanghai-based medical information industry player, Winning Health (SHE: 300253), has announced a partnership with Shanghai...

Company Deals

Thermo Fisher Scientific Expands Partnership with Sangon Biotech to Include GC/MS

Fineline Cube Nov 20, 2023

US-based life sciences giant Thermo Fisher Scientific Inc., (NYSE: TMO) has announced an expansion of...

Company Deals

Usynova Pharmaceuticals Inks Licensing Deal with AstraZeneca for KRASG12D Inhibitor UA022

Fineline Cube Nov 20, 2023

Shanghai-based Usynova Pharmaceuticals Ltd has announced a licensing agreement with UK pharmaceutical major AstraZeneca (AZ,...

Company Drug

Ascentage Pharma Secures Additional Indication Approval for Olverembatinib from NMPA

Fineline Cube Nov 20, 2023

China-based Ascentage Pharma (HKG: 6855) has announced receiving another indication approval from the National Medical...

Company

Aurobindo Pharma’s China Plant Secures EU GMP Approval, Eyes Revenue Generation

Fineline Cube Nov 20, 2023

India-based Aurobindo Pharma reportedly received EU GMP approval for its China-based manufacturing plant last week,...

Company Drug

CSPC Pharmaceutical Group Receives NMPA Approval for Phase II Clinical Study of ALMB-0168

Fineline Cube Nov 20, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from...

Company Drug

Apollomics’ Partner Avistone Wins Conditional Approval for c-Met Inhibitor in China

Fineline Cube Nov 20, 2023

US-based biotech Apollomics Inc., (NASDAQ: APLM) has announced that its Chinese partner, Beijing Avistone Pharmaceuticals...

Company Drug

Fosun Pharmaceutical Secures Clinical Trial Approvals for VT-101 in China and the US

Fineline Cube Nov 20, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced receiving clinical trial approvals for...

Posts pagination

1 … 473 474 475 … 698

Recent updates

  • Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II
  • TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal
  • Youcare Pharmaceutical Receives NMPA Approval for YKYY033 Clinical Trials Across Multiple Thrombotic Indications
  • Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody
  • Novo Nordisk Sues Eli Lilly Over Alleged False Advertising of Zepbound and Mounjaro in GLP-1 Market
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II

Company Deals

TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal

Company Drug

Youcare Pharmaceutical Receives NMPA Approval for YKYY033 Clinical Trials Across Multiple Thrombotic Indications

Company Deals

Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.